Tags

Type your tag names separated by a space and hit enter

[Immune-mediated neuropathies].
Rinsho Shinkeigaku. 2009 Nov; 49(11):956-8.RS

Abstract

Such neuropathies as Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and IgM paraproteinemic neuropathy are caused by autoimmune mechanisms. IgM paraproteinemic neuropathies are known to be intractable. Rituximab has recently been reported to be effective for IgM paraproteinemic neuropathy with anti-MAG IgM M-protein in a placebo-controlled trial. The effect should be confirmed with a larger trial. The use of this drug also may be tried for other type of IgM paraproteinemic neuropathy and for intractable CIDP in future. Antiganglioside IgG antibodies are frequently present in the acute-phase sera from GBS patients. Recently, presence of the antibodies that recognize a conformational epitope formed by carbohydrate portions of two different gangliosides (ganglioside complex) has been reported. Antibodies against a complex formed by GD1a and GD1b (anti-GD1a/GD1b antibodies) are associated with severe GBS. Anti-GM1/GalNAc-GD1a antibodies are found to be associated with pure motor GBS with frequent conduction block. Anti-ganglioside complex antibodies may be useful diagnostic and prognostic markers of GBS. Future study is necessary to clarify the pathogenetic mechanisms in which those antibodies are specifically involved.

Authors+Show Affiliations

Department of Neurology, Kinki University School of Medicine.

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

20030259

Citation

Kusunoki, Susumu. "[Immune-mediated Neuropathies]." Rinsho Shinkeigaku = Clinical Neurology, vol. 49, no. 11, 2009, pp. 956-8.
Kusunoki S. [Immune-mediated neuropathies]. Rinsho Shinkeigaku. 2009;49(11):956-8.
Kusunoki, S. (2009). [Immune-mediated neuropathies]. Rinsho Shinkeigaku = Clinical Neurology, 49(11), 956-8.
Kusunoki S. [Immune-mediated Neuropathies]. Rinsho Shinkeigaku. 2009;49(11):956-8. PubMed PMID: 20030259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Immune-mediated neuropathies]. A1 - Kusunoki,Susumu, PY - 2009/12/25/entrez PY - 2009/12/25/pubmed PY - 2010/9/3/medline SP - 956 EP - 8 JF - Rinsho shinkeigaku = Clinical neurology JO - Rinsho Shinkeigaku VL - 49 IS - 11 N2 - Such neuropathies as Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and IgM paraproteinemic neuropathy are caused by autoimmune mechanisms. IgM paraproteinemic neuropathies are known to be intractable. Rituximab has recently been reported to be effective for IgM paraproteinemic neuropathy with anti-MAG IgM M-protein in a placebo-controlled trial. The effect should be confirmed with a larger trial. The use of this drug also may be tried for other type of IgM paraproteinemic neuropathy and for intractable CIDP in future. Antiganglioside IgG antibodies are frequently present in the acute-phase sera from GBS patients. Recently, presence of the antibodies that recognize a conformational epitope formed by carbohydrate portions of two different gangliosides (ganglioside complex) has been reported. Antibodies against a complex formed by GD1a and GD1b (anti-GD1a/GD1b antibodies) are associated with severe GBS. Anti-GM1/GalNAc-GD1a antibodies are found to be associated with pure motor GBS with frequent conduction block. Anti-ganglioside complex antibodies may be useful diagnostic and prognostic markers of GBS. Future study is necessary to clarify the pathogenetic mechanisms in which those antibodies are specifically involved. SN - 0009-918X UR - https://www.unboundmedicine.com/medline/citation/20030259/[Immune_mediated_neuropathies]_ L2 - http://joi.jlc.jst.go.jp/JST.JSTAGE/clinicalneurol/49.956?from=PubMed DB - PRIME DP - Unbound Medicine ER -